Compound Muscle Action Potential (CMAP) Amplitude Trajectories and Pattern in Adults with 5q‐Spinal Muscular Atrophy Receiving Nusinersen Therapy: A Multicenter, Binational Observational Study
Authors:
- Bogdan BjelicaBogdan Bjelica
- Camilla WohnradeCWCamilla Wohnrade
- Alma OsmanovicAOAlma Osmanovic
- Olivia Schreiber‐KatzOSOlivia Schreiber‐Katz
- Sebastian HaecklSHSebastian Haeckl
- Maren FreigangMFMaren Freigang
- Isabell CordtsICIsabell Cordts
- Benedikt BeckerBBBenedikt Becker
- Charlotte VogtCVCharlotte Vogt
- Mohamad Tareq MuhandesMMMohamad Tareq Muhandes
Open Access
- 1 November 2025
- journal article
- research article
- Published by Wiley in European Journal of Neurology
- Vol. 32 (11) , e70405
Abstract
Background: This study aimed to evaluate changes in compound muscle action potential (CMAP) amplitude in adults with spinal muscular atrophy (SMA) undergoing nusinersen treatment and its association with motor function improvements. Methods: This multicenter study assessed median, ulnar, and peroneal CMAP over a follow‐up of up to 4.5 years using linear mixed models. Motor function was measured using the Revised Upper Limb Module (RULM) and the Hammersmith Functional Motor Scale Expanded (HFMSE). Correlations between CMAP and motor function scores were analyzed. Results: Seventy‐eight patients (27 ambulatory, 51 non‐ambulatory) were included. Baseline ulnar CMAP ≥ 2.0 mV distinguished SMA type 3 from type 2 with 91.3% sensitivity and 88.9% specificity (AUC 0.96, 95% CI 0.92–1.0), while baseline median nerve CMAP ≥ 6.5 mV showed 91.7% sensitivity and 77.3% specificity (AUC 0.84, 95% CI 0.72–0.96). No significant changes over time were observed in median, ulnar, and peroneal CMAP amplitudes ( p > 0.05). CMAP trajectories did not differ between SMA types 2 and 3 ( p > 0.05). No significant difference in the change in RULM or HFMSE at any time point was observed between SMA patients with baseline median nerve CMAP < 5 mV and those with CMAP of ≥ 5 mV ( p > 0.05). No significant correlations were found between changes in median nerve CMAP and HFMSE or RULM ( p > 0.05). Discussion: CMAP amplitudes remained stable during nusinersen treatment, with no differences in trajectories between SMA types 2 and 3. Our findings suggest that while CMAP amplitude correlates with disease severity, it may not serve as a sensitive biomarker of treatment response in adult SMA patients.Keywords
This publication has 36 references indexed in Scilit:
- Motor Unit Number Index (MUNIX) of hand muscles is a disease biomarker for adult spinal muscular atrophyClinical Neurophysiology, 2019
- SMArtCARE - A platform to collect real-life outcome data of patients with spinal muscular atrophyOrphanet Journal of Rare Diseases, 2019
- Ambulatory function in spinal muscular atrophy: Age-related patterns of progressionPLOS ONE, 2018
- Nusinersen versus Sham Control in Later-Onset Spinal Muscular AtrophyNew England Journal of Medicine, 2018
- Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular AtrophyNew England Journal of Medicine, 2017
- Revised upper limb module for spinal muscular atrophy: Development of a new moduleMuscle & Nerve, 2016
- Electrophysiological biomarkers in spinal muscular atrophy: proof of conceptAnnals of Clinical and Translational Neurology, 2013
- Natural history of denervation in SMA: Relation to age, SMN2 copy number, and functionAnnals of Neurology, 2005
- The Hammersmith Functional Motor Scale for Children with Spinal Muscular Atrophy: a Scale to Test Ability and Monitor Progress in Children with Limited AmbulationEuropean Journal of Paediatric Neurology, 2003
- Identification and characterization of a spinal muscular atrophy-determining geneCell, 1995